Back to top

cell-therapy: Archive

Zacks Equity Research

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.

AGENPositive Net Change ADPTNegative Net Change ALLONegative Net Change ELEVPositive Net Change

Zacks Equity Research

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

BEAMPositive Net Change ADPTNegative Net Change IOVANegative Net Change ELEVPositive Net Change